

NCT01116882 Raw comparison:

Summary:
CHIA has 35 criteria while your personal folder has 39 criteria
Total found criteria: 34/35
Total not Found: 1/35
Total Extra: 4
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subject is at least 18 years old                   │ Subject is at least 18 years old                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject requires single- or multi-vessel           │ Subject requires single- or multi-vessel           │
│ percutaneous coronary intervention (PCI) of de     │ percutaneous coronary intervention (PCI) of de     │
│ novo or restenotic target lesion (including in-    │ novo or restenotic target lesion (including in-    │
│ stent restenotic lesions)                          │ stent restenotic lesions)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject's lesion(s) is (are) amenable to stent     │ Subject's lesion(s) is (are) amenable to stent     │
│ treatment with currently available FDA-approved    │ treatment with currently available FDA-approved    │
│ bare metal or drug eluting stents                  │ bare metal or drug eluting stents                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is an acceptable candidate for elective    │ Subject is an acceptable candidate for elective    │
│ urgent or emergency coronary artery bypass graft   │ urgent or emergency coronary artery bypass graft   │
│ (CABG)                                             │ (CABG)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has clinical evidence of ischemic heart    │ Subject has clinical evidence of ischemic heart    │
│ disease in terms of a positive functional study or │ disease in terms of a positive functional study or │
│ documented symptoms                                │ documented symptoms                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented stable angina pectoris [Canadian        │ Documented stable angina pectoris \[Canadian       │
│ Cardiovascular Society Classification (CCS) 1 2 3  │ Cardiovascular Society Classification (CCS) 1 2 3  │
│ or 4] unstable angina pectoris with documented     │ or 4\] unstable angina pectoris with documented    │
│ ischemia (Braunwald Class IB-C IIB-C or IIIB-C)    │ ischemia (Braunwald Class IB-C IIB-C or IIIB-C)    │
│ non-ST segment elevation myocardial infarction or  │ non-ST segment elevation myocardial infarction or  │
│ documented silent ischemia                         │ documented silent ischemia                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is willing and able to undergo             │ Subject is willing and able to undergo             │
│ percutaneous intervention at SOS hospital if       │ percutaneous intervention at SOS hospital if       │
│ randomized to SOS study arm                        │ randomized to SOS study arm                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject and the treating physician agree that the  │ Subject and the treating physician agree that the  │
│ subject will comply with all follow-up evaluations │ subject will comply with all follow-up evaluations │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has been informed of the nature of the     │ Subject has been informed of the nature of the     │
│ study and agrees to its provisions and has         │ study and agrees to its provisions and has         │
│ provided written informed consent as approved by   │ provided written informed consent as approved by   │
│ the Institutional Review Board/Ethics Committee of │ the Institutional Review Board/Ethics Committee of │
│ the respective clinical site                       │ the respective clinical site                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The target lesion(s) is (are) de novo or           │ The target lesion(s) is (are) de novo or           │
│ restenotic (including in-stent restenotic) native  │ restenotic (including in-stent restenotic) native  │
│ coronary artery lesion(s) with greater than 50 and │ coronary artery lesion(s) with greater than 50 and │
│ less than 100% stenosis (visual estimate) or the   │ less than 100% stenosis (visual estimate) or the   │
│ target lesion is an acute (less than 1 month)      │ target lesion is an acute (less than 1 month)      │
│ total occlusion as evidenced by clinical symptoms  │ total occlusion as evidenced by clinical symptoms  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Target lesions(s) is (are) located in an infarct   │ Target lesions(s) is (are) located in an infarct   │
│ (if not treated with primary PCI) or non-infarct-  │ (if not treated with primary PCI) or non-infarct-  │
│ related artery with a 70% or greater stenosis (by  │ related artery with a 70% or greater stenosis (by  │
│ visual estimate) more than 72 hours following the  │ visual estimate) more than 72 hours following the  │
│ ST segment elevation myocardial infarction (STEMI) │ ST segment elevation myocardial infarction (STEMI) │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The patient is pregnant or breastfeeding           │ The patient is pregnant or breastfeeding           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of STEMI within 72 hours of the intended  │ Evidence of STEMI within 72 hours of the intended  │
│ treatment on infarct related or non-infarct        │ treatment on infarct related or non-infarct        │
│ related artery                                     │ related artery                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cardiogenic shock on presentation or during        │ Cardiogenic shock on presentation or during        │
│ current hospitalization                            │ current hospitalization                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction less than 20%   │ Left ventricular ejection fraction less than 20%   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known allergies to aspirin clopidogrel (Plavix)    │ Known allergies to aspirin clopidogrel (Plavix)    │
│ and ticlopidine (Ticlid) heparin bivalirudin       │ and ticlopidine (Ticlid) heparin bivalirudin       │
│ stainless steel or contrast agent (which cannot be │ stainless steel or contrast agent (which cannot be │
│ adequately premedicated)                           │ adequately premedicated)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A platelet count less than 75 000 cells/mm3 or     │ A platelet count less than 75 000 cells/mm3 or     │
│ greater than 700 000 cells/mm3 or a WBC less than  │ greater than 700 000 cells/mm3 or a WBC less than  │
│ 3 000 cells/mm3                                    │ 3 000 cells/mm3                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute or chronic renal dysfunction (creatinine     │ Acute or chronic renal dysfunction (creatinine     │
│ greater than 2 5 mg/dl or less than 150µmol/L)     │ greater than 2 5 mg/dl or less than 150µmol/L)     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is currently participating in an           │ Subject is currently participating in an           │
│ investigational drug or device study that has not  │ investigational drug or device study that has not  │
│ completed the primary endpoint or that clinically  │ completed the primary endpoint or that clinically  │
│ interferes with the current study endpoints (Note  │ interferes with the current study endpoints (Note  │
│ Trials requiring extended follow-up for products   │ Trials requiring extended follow-up for products   │
│ that were investigational but have since become    │ that were investigational but have since become    │
│ commercially available are not considered          │ commercially available are not considered          │
│ investigational trials)                            │ investigational trials)                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior participation in this study                  │ Prior participation in this study                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Within 30 days prior to the index study procedure  │ Within 30 days prior to the index study procedure  │
│ the subject has undergone a previous coronary      │ the subject has undergone a previous coronary      │
│ interventional procedure of any kind Note This     │ interventional procedure of any kind Note This     │
│ exclusion criterion does not apply to post-STEMI   │ exclusion criterion does not apply to post-STEMI   │
│ patients                                           │ patients                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stroke or transient ischemic attack within the     │ Stroke or transient ischemic attack within the     │
│ prior 3 months                                     │ prior 3 months                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active peptic ulcer or upper gastrointestinal      │ Active peptic ulcer or upper gastrointestinal      │
│ bleeding within the prior 3 months                 │ bleeding within the prior 3 months                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has active sepsis                          │ Subject has active sepsis                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unprotected left main coronary artery disease      │ Unprotected left main coronary artery disease      │
│ (stenosis greater than 50%)                        │ (stenosis greater than 50%)                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the investigator's opinion subject has a co-    │ In the investigator's opinion subject has a co-    │
│ morbid condition(s) that could limit the life      │ morbid condition(s) that could limit the life      │
│ expectancy to less than one year or limit the      │ expectancy to less than one year or limit the      │
│ subject's ability to participate in the study or   │ subject's ability to participate in the study or   │
│ comply with follow-up requirements or impact the   │ comply with follow-up requirements or impact the   │
│ scientific integrity of the study                  │ scientific integrity of the study                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has normal or insignificant coronaries (i  │ Subject has normal or insignificant coronaries (i  │
│ e coronary lesion(s) less than 50% stenosis)       │ e coronary lesion(s) less than 50% stenosis)       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any target vessel has evidence of                  │ Any target vessel has evidence of                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ excessive thrombus (e g requires target vessel     │ excessive thrombus (e g requires target vessel     │
│ thrombectomy)                                      │ thrombectomy)                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ tortuousity (greater than 60 degree angle) that    │ tortuousity (greater than 60 degree angle) that    │
│ makes it unsuitable for proper stent delivery and  │ makes it unsuitable for proper stent delivery and  │
│ deployment                                         │ deployment                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ heavy calcification                                │ heavy calcification                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any target lesion requires treatment with a device │ Any target lesion requires treatment with a device │
│ other than percutaneous transluminal coronary      │ other than percutaneous transluminal coronary      │
│ angioplasty (PTCA) prior to stent placement (e g   │ angioplasty (PTCA) prior to stent placement (e g   │
│ but not limited to directional coronary            │ but not limited to directional coronary            │
│ atherectomy excimer laser rotational atherectomy   │ atherectomy excimer laser rotational atherectomy   │
│ etc )                                              │ etc )                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any lesion that is located in a saphenous vein     │ Any lesion that is located in a saphenous vein     │
│ graft however lesions located within the native    │ graft however lesions located within the native    │
│ vessel but accessed through the graft are eligible │ vessel but accessed through the graft are eligible │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The target vessel is in a "last remaining"         │ The target vessel is in a "last remaining"         │
│ epicardial vessel (e g greater than 2 non-target   │ epicardial vessel (e g greater than 2 non-target   │
│ epicardial vessels and the bypass grafts to these  │ epicardial vessels and the bypass grafts to these  │
│ territories [if present] are totally occluded)     │ territories \[if present\] are totally occluded)   │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                │
╞════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol  │
│ inclusion/exclusion criteria listed above and below with the exception that a target lesion of 70% │
│ or greater stenosis may be treated with or without symptoms or abnormal stress test)               │
╘════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                           │
╞═══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Lesions treated with PCI more than 72 hours following STEMI would be subject to the same protocol │
│ inclusion/                                                                                        │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ listed above and below with the exception that a target lesion of 70% or greater stenosis may be  │
│ treated with or without symptoms or abnormal stress test)                                         │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Exclusion Criteria                                                                                │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                 │
╘═══════════════════════════════════════════════════════════════════════════════════════════════════╛